Second-Line Afatinib Increases Progression-Free Survival (PFS) in Metastatic Head and Neck Cancer

During a press conference at ESMO 2014, Dr Jean-Pascal Machiels, Cliniques Universitaires St. Luc, Brussels, Belgium, presents the results of a Phase III study looking at the impact of afatinib versus methotrexate upon progression-free survival in patients with head and neck cancer after failure of platinum-based chemotherapy.

Year of Production:
Running Time:
Color/Sound:

2014
04:58
Color/Sound

Comments are closed.